Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial
The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the